Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Metavivor Announces the Stage IV Stampede and Launch of the 2019-2020 Advocacy Agenda

Metavivor presents its advocacy initiative to help increase funding for research and to improve access to benefits for people with stage IV, metastatic cancer


News provided by

METAvivor Research and Support, Inc

Oct 08, 2019, 10:50 ET

Share this article

Share toX

Share this article

Share toX

Stage IV Stampede on Washington D.C. for Metastatic Breast Cancer - October 10-11, 2019
Stage IV Stampede on Washington D.C. for Metastatic Breast Cancer - October 10-11, 2019

ANNAPOLIS, Md., Oct. 8, 2019 /PRNewswire-PRWeb/ -- METAvivor Research and Support Inc., a non-profit organization dedicated to funding research for Stage IV, metastatic breast cancer, announced the launch of its Stage IV Stampede campaign. The campaign will commence with two days of action and education on October 10 and 11, 2019 in Washington, DC that will include an advocacy boot camp, a march, a Die-In (hosted by partner MET-UP), and visits with Congressional offices. The day of action is the beginning of a focused, grassroots advocacy and awareness-raising effort to request increased funding for research on stage IV metastatic cancer, to encourage NCI and CDC to count those with metastatic disease and to request expedited access to healthcare and benefits for people with stage IV disease.

Metastatic breast cancer (also known as stage IV or advanced stage cancer) is the spread of breast cancer to non-adjacent parts of the body -- most commonly to the bones, liver, lungs and/or brain. Currently, metastatic breast cancer is minimally treatable, but not survivable. Much of the current metastatic cancer research is focused on preventing metastasis rather than trying to save the lives of those who have already metastasized. Metastatic breast cancer accounts for 99% of the more than 41,000 annual deaths due to breast cancer. Metastases is not unique to breast cancer, all cancers can and do metastasize thus, approximately 600,000 Americans continue to perish each year as a result, and 90% of those individuals die from cancers that have spread.

Metavivor's Stage IV Stampede, march on Washington DC is in its third year. More than 230 metastatic breast cancer patients will convene on Washington DC for two days of training, marching and congressional visits to enlighten leaders about the need for additional metastatic cancer research.

Post this

METAvivor has partnered with a number of organizations for the event, including Living Beyond Breast Cancer, the Male Breast Cancer Coalition, MET-Up and For the Breast of Us to help share the importance of advocating for addition Corporate sponsors of the advocacy plan include Novartis, Pfizer, Seattle Genetics and Eisai.

The coalition of organizations is focused on achieving the following specific goals:

1. Expand the metastatic cancer research portfolio at the National Institutes of Health (NIH) in Fiscal Year (FY) 2019 & FY 2020 through growth in appropriations and demonstrated congressional interest in controlling and eliminating cancer that has already disseminated (metastasized).

2. Ensure the continued growth of the Breast Cancer Research Program (BCRP) within the Congressionally Directed Medical Research Program (CDMRP) at the Department of Defense (DoD) in FY 2019 and FY 2020, and encourage prioritization of research opportunities for already disseminated, metastatic, stage IV cancers since eliminating breast cancer through prevention has failed.

3. Raise awareness of already disseminated, metastatic, stage IV cancer and the unique needs of affected individuals on Capitol Hill and among the general public and advocate the need for new codes for patients with a diagnosis of already disseminated, metastatic cancer so that this population can be correctly counted in the SEER database.

4. Support efforts to protect metastatic cancer patients access to quality, affordable healthcare, innovative therapies, and end the waiting period for disability and Medicare benefits for individuals facing terminal illness.

5. Support efforts to ensure new treatment options for metastatic cancer patients, in all forms, are available and are treated equally and that there is no drug disparity.

Michael Kovarik, Vice President of METAvivor, said, "METAvivor is pleased to partner with organizations, patients and supporters to launch this critical advocacy program. We believe that it is vital that we change the conversation around breast cancer to include a focus on stage IV metastatic breast cancer and the need for social services and research funding. We have the potential to make a significant difference in the survival of many metastatic patients but we cannot do this without substantial change in how we fund research."

To learn more about METAvivor's Stage IV Stampede visit Metavivor Stage IV Stampede.

ABOUT METAVIVOR

METAvivor Research and Support Inc. is an Annapolis-based, 501(c)(3), non-profit organization founded by metastatic breast cancer (MBC) patients in 2009. METAvivor's main mission is to fund research for metastatic breast cancer. The organization also works to raise awareness of MBC, provide education and support for people living with the disease, and offers many opportunities for others to help make a difference for the metastatic community. 100% of all donations made to METAvivor go to fund critical research that will lead to advances in treatment options, quality of life and survival for patients diagnosed with MBC.

Since 2009, METAvivor has expanded nationwide and awarded over $7.4 million in research grants for stage IV metastatic breast cancer. METAvivor has gained a rapidly growing following within the breast cancer community and has become a leader in its field. METAvivor is the only national organization with a peer-reviewed grant program aimed at exclusively funding Metastatic Breast Cancer research.

Visit us at METAvivor.org, and follow us on Facebook, Instagram and Twitter.

SOURCE METAvivor Research and Support, Inc

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.